D-Sight — Seed · €1M

Clave Capital invested €1M through its Clave Innohealth fund in D-Sight, a newly created spin-off of the Vall d'Hebron Research Institute (VHIR) developing therapies for diabetic retinopathy and other neurodegenerative retinal diseases such as glaucoma. It was the third investment from the Innohealth fund, after Innitius and Fisify.